BTL Industries v. Pari’s Medspa: HIFEM Patent Suit Dismissed Without Prejudice
BTL Industries, Inc., holder of US10478634B2 covering high-intensity electromagnetic muscle stimulation technology, sued a Texas medical spa and its owner over alleged use of EMSLIM and HIEMT devices. The case was voluntarily dismissed without prejudice in just 114 days — leaving the door open for refiling.
Swift voluntary dismissal in the aesthetic HIFEM device IP space
On 1 November 2023, BTL Industries, Inc. filed a patent infringement action in the Eastern District of Texas (Case No. 4:23-cv-00985) against Pari’s Medspa and its individual operator Syed Najam Jaffri. The complaint centred on US10478634B2, a patent covering high-intensity focused electromagnetic (HIFEM) muscle stimulation technology, and alleged unauthorised use of EMSLIM, EMSLIM NEO, and HIEMT-branded devices — competing products in the non-invasive body contouring market.
The case closed on 23 February 2024, just 114 days after filing, when BTL Industries filed a Notice of Voluntary Dismissal. Chief Judge Amos L. Mazzant ordered both defendants dismissed without prejudice. Because the dismissal is without prejudice, BTL retains the legal right to bring the same claims against Pari’s Medspa and Syed Najam Jaffri in future proceedings — the merits of the infringement allegations were never adjudicated.
The speed of resolution — under four months — suggests the matter was resolved or reconsidered before any substantive litigation milestones such as claim construction or discovery. Whether the parties reached a private settlement, a licensing arrangement, or BTL simply elected to withdraw and regroup is not disclosed in the public record. The without-prejudice framing is a notable preservation of optionality for BTL, consistent with an enforcement campaign targeting multiple medspa operators.
Filing to resolution in 114 days
114 days — resolved well under the typical 2–3 year patent infringement timeline
Voluntarily dismissed without prejudice — what this means for both parties
Voluntary dismissal: plaintiff’s unilateral exit
A voluntary dismissal under Fed. R. Civ. P. 41(a) allows a plaintiff to withdraw its complaint without a court ruling on the merits. Filed before the defendant serves an answer or motion for summary judgment, it requires no judicial approval. BTL chose this path, signalling that it — not the court — controlled the exit. No finding of liability, invalidity, or non-infringement was made.
Rule 41(a) — plaintiff-initiatedWithout prejudice: BTL’s claims remain alive
A dismissal without prejudice means the case ends but the claims do not. BTL may refile the same infringement allegations against Pari’s Medspa and Syed Najam Jaffri in the future. By contrast, a dismissal with prejudice would permanently bar refiling. The public record here confirms the without-prejudice designation — offering no indication of why BTL withdrew or whether any agreement was reached privately.
Claims preserved — refiling permittedDefendants face continued uncertainty
For Pari’s Medspa and Syed Najam Jaffri, dismissal without prejudice is a temporary reprieve rather than a clean resolution. They cannot rely on this outcome as a defence in any future action by BTL. If they continue operating the allegedly infringing EMSLIM or HIEMT devices, they remain exposed to a new complaint. Defendants seeking certainty would typically pursue a formal covenant not to sue or a licensing agreement.
Ongoing exposure for defendantsMedspa targeting: a broader BTL strategy?
Filing against a small medspa operator and its individual owner is consistent with a systematic enforcement campaign against downstream users of competing HIFEM devices. BTL’s EMSCULPT product line competes directly with EMSLIM and HIEMT-branded equipment. Targeting individual clinics can pressure supply chains and deter adoption of competing devices, even when cases resolve quickly without public merits rulings.
Downstream enforcement signalFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | BTL Industries, Inc. | Company | Medical technology company — holder of US10478634B2 covering HIFEM body contouringSearch in Eureka ↗ |
| Defendant | Pari’s Medspa | Company | Texas medical spa operator and its individual owner, alleged users of infringing HIFEM devicesSearch in Eureka ↗ |
| Plaintiff counsel | Ryan D. Levy | Attorney | Counsel for BTL Industries, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Amos L. Mazzant | Chief Judge | Texas Eastern District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The court’s order mirrors BTL’s voluntary dismissal notice verbatim, confirming that both named defendants — Pari’s Medspa and Syed Najam Jaffri — are dismissed without prejudice. The order is purely procedural: it makes no ruling on infringement, validity, or claim construction. For defendants, the absence of a merits ruling means they cannot invoke issue preclusion or claim victory. For BTL, it means full optionality to refile under the same patent against the same parties.
US10478634B2 — High-Intensity Electromagnetic Muscle Stimulation
US10478634B2, filed under application number US16/034793, protects a method and apparatus for high-intensity focused electromagnetic (HIFEM) stimulation of muscle tissue for non-invasive body contouring and muscle toning. The patent sits at the core of BTL Industries’ EMSCULPT product line — a commercially significant aesthetic technology that induces supramaximal muscle contractions using focused electromagnetic fields. The technology domain spans both aesthetic medicine and rehabilitative muscle stimulation.
US10478634B2 is strategically significant because the HIFEM segment has attracted a wave of lower-cost competitors — including EMSLIM, EMSLIM NEO, and HIEMT-branded devices — predominantly manufactured in China and distributed to medspas globally. BTL appears to be using this patent as a primary enforcement asset to protect market share in the non-invasive body sculpting sector. Any company manufacturing, importing, distributing, or operating HIFEM-type devices in the US should treat this patent as a live enforcement risk.
Should you run an FTO check against US10478634B2?
If your clinic, distribution business, or device brand touches EMSLIM, EMSLIM NEO, HIEMT, or any HIFEM electromagnetic body contouring product, US10478634B2 is directly relevant to your risk profile. This case demonstrates BTL’s willingness to pursue end-user operators — not just device makers. An FTO assessment should map your specific device’s operating parameters and electromagnetic stimulation methods against BTL’s granted claims.
PatSnap Eureka’s FTO Search Agent can run a structured claim-by-claim analysis against US10478634B2 in minutes, surfacing prosecution history, claim scope, and prior art that may constrain BTL’s enforcement reach. Ongoing claim monitoring through Eureka will alert your IP team to any continuation patents or reissue applications that could extend BTL’s coverage into adjacent HIFEM device configurations.
Run a freedom-to-operate analysis on US10478634B2 to assess your product’s exposure
Run FTO in Eureka →Similar HIFEM and aesthetic device patent infringement cases
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the aesthetic device IP landscape
BTL’s rapid-fire enforcement and without-prejudice exit raise pointed questions about HIFEM patent scope, medspa liability exposure, and the cost of operating third-party devices.
Medical spas face direct infringement risk as device end-users
This case confirms that BTL is willing to name individual clinic operators — not just device manufacturers — as defendants. Medspas operating EMSLIM, HIEMT, or HIFEM-branded equipment from third-party vendors should conduct FTO diligence before deployment. Patent infringement liability can attach at the point of use, not just manufacture.
Without-prejudice exits preserve plaintiff leverage in settlement talks
A voluntary dismissal without prejudice is frequently used as a tactical tool: the complaint creates pressure, and if terms are reached privately, the plaintiff exits cleanly while retaining the right to refile if the agreement breaks down. IP teams monitoring BTL enforcement should treat these dispositions as potential licensing outcomes rather than defeats.
BTL v Pari’s — key questions answered
BTL Industries filed a patent infringement complaint against Pari’s Medspa and Syed Najam Jaffri in the Eastern District of Texas on 1 November 2023, alleging infringement of US10478634B2 through use of EMSLIM and HIEMT devices. The case was voluntarily dismissed without prejudice on 23 February 2024, 114 days after filing, with no merits ruling issued.
Dismissal without prejudice means BTL Industries retains the right to refile the same patent infringement claims against Pari’s Medspa and Syed Najam Jaffri in the future. No finding was made on whether the defendants infringed US10478634B2. The defendants cannot use this outcome as a legal defence in any subsequent action brought by BTL.
US10478634B2 covers a method and apparatus for high-intensity focused electromagnetic (HIFEM) stimulation designed to induce muscle contractions for non-invasive body contouring. It is the foundational patent behind BTL’s EMSCULPT product line and is asserted against competing EMSLIM, EMSLIM NEO, and HIEMT-branded devices in this and related enforcement actions.
End-user operators of patented technology can face direct infringement liability even if they did not manufacture the device. Suing medspa operators is consistent with a downstream enforcement strategy that creates pressure across the supply chain — deterring clinics from adopting competing HIFEM devices regardless of the manufacturer. This approach can be more cost-effective than pursuing overseas device makers.
The Eastern District of Texas has historically been considered a plaintiff-favourable patent litigation venue, with established procedures and scheduling norms that can favour patentees. BTL’s choice to file there against a Texas medspa — rather than in a defendant’s home district — suggests a deliberate venue strategy, though the public record does not confirm this as part of a broader multi-case filing pattern in that district.
PatSnap Eureka searches patents and litigation data to answer instantly.